These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25600174)

  • 1. Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients.
    Pescosolido N; Gatto V; Stefanucci A; Rusciano D
    Ophthalmic Physiol Opt; 2015 Mar; 35(2):201-5. PubMed ID: 25600174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular pressure changes following topical ocular hypotensive medications washout.
    Ho H; Daas A; Ho J; Alaghband P; Galvis EA; de Antonio Ramirez A; Grassi P; Lim R; Lim KS
    Br J Ophthalmol; 2021 Feb; 105(2):205-209. PubMed ID: 32277009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions.
    Martínez-Águila A; Fonseca B; Bergua A; Pintor J
    Eur J Pharmacol; 2013 Feb; 701(1-3):213-7. PubMed ID: 23270715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
    King AJ; Rotchford AP
    JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy.
    Vetrugno M; Uva MG; Russo V; Iester M; Ciancaglini M; Brusini P; Centofanti M; Rossetti LM
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):536-41. PubMed ID: 22731245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
    Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
    J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study.
    Jabbarpoor Bonyadi MH; Yazdani S; Saadat S
    BMC Complement Altern Med; 2014 Oct; 14():399. PubMed ID: 25319729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
    Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO
    Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma.
    Prünte C; Flammer J
    Ophthalmology; 1995 Sep; 102(9):1291-7. PubMed ID: 9097765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension.
    Narayanaswamy A; Neog A; Baskaran M; George R; Lingam V; Desai C; Rajadhyaksha V
    Indian J Ophthalmol; 2007; 55(2):127-31. PubMed ID: 17322603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latanoprost treatment differentially affects intraocular pressure readings obtained with three different tonometers.
    Sánchez-Barahona C; Bolívar G; Katsanos A; Teus MA
    Acta Ophthalmol; 2019 Dec; 97(8):e1112-e1115. PubMed ID: 31184426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
    Natt NK; Gupta A; Singh G; Singh T
    Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
    Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
    Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.